Details
| Stereochemistry | RACEMIC |
| Molecular Formula | C17H26ClN3O3 |
| Molecular Weight | 355.86 |
| Optical Activity | ( + / - ) |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CCN(CC)CCNC(=O)C1=CC(Cl)=C(N)C=C1OC(C)C(C)=O
InChI
InChIKey=ZYOJXUNLLOBURP-UHFFFAOYSA-N
InChI=1S/C17H26ClN3O3/c1-5-21(6-2)8-7-20-17(23)13-9-14(18)15(19)10-16(13)24-12(4)11(3)22/h9-10,12H,5-8,19H2,1-4H3,(H,20,23)
Batanopride, previously known as BMY-25801, a 5-hydroxytryptamine 3 receptor antagonist, was studied against emesis for cancer patients that were treated by chemotherapy procedure. Batanopride had the dose-limiting side effects including hypotension and long QT syndrome that is why any further experiments for its medical application were discontinued.
Originator
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| A randomized, double-blinded study comparing six doses of batanopride (BMY-25801) with methylprednisolone in patients receiving moderately emetogenic chemotherapy. | 1991-10 |
|
| Dose-limiting hypotension with the 5-HT3-antagonist batanopride (BMY-25801). | 1991-02 |
|
| BMY-25801, an antiemetic agent free of D2-dopamine receptor antagonist properties. | 1988-03 |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/1742224
six patient groups each received a single intravenous dose of batanopride ranging from 0.2 to 6.0 mg/kg
Route of Administration:
Intravenous
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C267
Created by
admin on Mon Mar 31 18:23:14 GMT 2025 , Edited by admin on Mon Mar 31 18:23:14 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
DTXSID20869373
Created by
admin on Mon Mar 31 18:23:14 GMT 2025 , Edited by admin on Mon Mar 31 18:23:14 GMT 2025
|
PRIMARY | |||
|
6420
Created by
admin on Mon Mar 31 18:23:14 GMT 2025 , Edited by admin on Mon Mar 31 18:23:14 GMT 2025
|
PRIMARY | |||
|
SUB06108MIG
Created by
admin on Mon Mar 31 18:23:14 GMT 2025 , Edited by admin on Mon Mar 31 18:23:14 GMT 2025
|
PRIMARY | |||
|
BATANOPRIDE
Created by
admin on Mon Mar 31 18:23:14 GMT 2025 , Edited by admin on Mon Mar 31 18:23:14 GMT 2025
|
PRIMARY | |||
|
C060190
Created by
admin on Mon Mar 31 18:23:14 GMT 2025 , Edited by admin on Mon Mar 31 18:23:14 GMT 2025
|
PRIMARY | |||
|
100000088431
Created by
admin on Mon Mar 31 18:23:14 GMT 2025 , Edited by admin on Mon Mar 31 18:23:14 GMT 2025
|
PRIMARY | |||
|
59692
Created by
admin on Mon Mar 31 18:23:14 GMT 2025 , Edited by admin on Mon Mar 31 18:23:14 GMT 2025
|
PRIMARY | |||
|
C1021
Created by
admin on Mon Mar 31 18:23:14 GMT 2025 , Edited by admin on Mon Mar 31 18:23:14 GMT 2025
|
PRIMARY | |||
|
1AT99K728N
Created by
admin on Mon Mar 31 18:23:14 GMT 2025 , Edited by admin on Mon Mar 31 18:23:14 GMT 2025
|
PRIMARY | |||
|
CHEMBL38594
Created by
admin on Mon Mar 31 18:23:14 GMT 2025 , Edited by admin on Mon Mar 31 18:23:14 GMT 2025
|
PRIMARY | |||
|
102670-46-2
Created by
admin on Mon Mar 31 18:23:14 GMT 2025 , Edited by admin on Mon Mar 31 18:23:14 GMT 2025
|
PRIMARY |
ACTIVE MOIETY
METABOLITE (PARENT)
METABOLITE (PARENT)
SALT/SOLVATE (PARENT)